The newly allowed U.S. patents focus on 2-bromolysergic acid diethylamide hydrobromide, the specific salt form Ceruvia intends to bring to market. By securing rights to both this crystalline structure and high-purity manufacturing methods—including routes derived from bromocriptine—the company aims to ensure formulation stability and long-term shelf life. This intellectual property portfolio is expected to provide coverage through 2042, potentially offering the company a pathway for FDA Orange Book listing and regulatory patent-term extensions.
In section Releases
Ceruvia Secures Patent Protection for BOL-148 Cluster Headache Treatment
Ceruvia Lifesciences has secured three U.S. patent allowances and a European Unitary Patent for BOL-148, its non-hallucinogenic LSD analog. These protections cover the proprietary crystalline form and manufacturing processes of the drug, which is currently being developed to address the significant clinical needs of patients suffering from cluster headaches.
Carey Turnbull, founder and CEO of Ceruvia, emphasized that the transition from a known scientific molecule to a commercial pharmaceutical requires rigorous development. The company’s research, conducted alongside partners like Curia, resulted in a non-hygroscopic material designed for scalable production. With $8 million in fresh funding, Ceruvia is preparing to launch an integrated Phase 1/2 clinical program. The company plans to submit a Clinical Trial Application in Germany this September, targeting the first patient enrollment by the end of 2026.
Comments (0)
No comments yet. Be the first!